NewLink Genetics Corp (NLNK) Receives $25.67 Average Target Price from Analysts

Shares of NewLink Genetics Corp (NASDAQ:NLNK) have earned a consensus rating of “Buy” from the eight analysts that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $25.67.

NLNK has been the topic of a number of recent analyst reports. Robert W. Baird upgraded NewLink Genetics from a “neutral” rating to an “outperform” rating and raised their target price for the stock from $8.00 to $22.00 in a report on Friday, September 8th. ValuEngine cut NewLink Genetics from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Stifel Nicolaus raised their target price on NewLink Genetics from $14.00 to $29.00 and gave the stock a “buy” rating in a report on Monday, September 11th. Bank of America initiated coverage on NewLink Genetics in a report on Friday, October 13th. They set a “buy” rating and a $22.00 target price on the stock. Finally, Jefferies Group reduced their target price on NewLink Genetics from $26.00 to $25.00 and set a “buy” rating on the stock in a report on Friday, November 3rd.

In other NewLink Genetics news, major shareholder Stine Seed Farm, Inc. acquired 780,487 shares of the business’s stock in a transaction dated Friday, October 6th. The shares were acquired at an average price of $10.25 per share, for a total transaction of $7,999,991.75. Following the acquisition, the insider now directly owns 7,857,732 shares of the company’s stock, valued at approximately $80,541,753. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 13.70% of the stock is currently owned by company insiders.

Large investors have recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of NewLink Genetics by 1,823.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,269 shares of the biotechnology company’s stock valued at $105,000 after purchasing an additional 9,735 shares in the last quarter. Oppenheimer & Co. Inc. bought a new position in shares of NewLink Genetics during the 3rd quarter valued at about $114,000. UBS Asset Management Americas Inc. bought a new position in shares of NewLink Genetics during the 1st quarter valued at about $297,000. State of Wisconsin Investment Board bought a new position in shares of NewLink Genetics during the 2nd quarter valued at about $125,000. Finally, Advisor Group Inc. lifted its holdings in shares of NewLink Genetics by 3.4% during the 2nd quarter. Advisor Group Inc. now owns 18,082 shares of the biotechnology company’s stock valued at $133,000 after purchasing an additional 600 shares in the last quarter. Institutional investors and hedge funds own 52.35% of the company’s stock.

Shares of NewLink Genetics (NASDAQ:NLNK) traded up $0.09 on Monday, reaching $8.86. The company’s stock had a trading volume of 756,542 shares, compared to its average volume of 927,664. NewLink Genetics has a 12-month low of $5.90 and a 12-month high of $25.17.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by Week Herald and is owned by of Week Herald. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://weekherald.com/2017/12/12/newlink-genetics-corp-nlnk-receives-25-67-average-target-price-from-analysts.html.

About NewLink Genetics

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Analyst Recommendations for NewLink Genetics (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corp and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply